Shanghai Golden Leaf Med Tec Co., Ltd, a specialist in interventional treatments based in China, has reportedly secured “hundreds of millions” of renminbi in a Series D financing round. The round was led by ZhongPing Capital, with participation from Shanghai Healthcare Capital, Dingxin Capital, and Morning Spring Venture. The funds raised will be directed towards the commercial promotion of the company’s percutaneous renal artery sympathetic radiofrequency ablation (RDN) product for the treatment of hypertension, pending approval. Additionally, the capital will support global multi-center regulatory studies for the RDN product, global multi-center studies for transvascular sympathetic denervation radiofrequency ablation (EDN) for type 2 diabetes, and research and development, regulatory filing, and market development for other core products.
Founded in 2013, Golden Leaf Med Tec initially focused on the cardiovascular field and has since expanded its energy platform to address multiple chronic diseases, including hypertension, diabetes, chronic obstructive pulmonary disease, and heart failure. The company’s expansion and optimization of its energy platform have allowed it to delve deeper into these areas, aiming to provide innovative solutions for patients suffering from these conditions.- Flcube.com
